Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study - 14/03/18
Doi : 10.1016/j.jaad.2017.10.051
Miguel Angel Descalzo, MSc, PhD a, ⁎ 
, Gregorio Carretero, MD, PhD b, Carlos Ferrándiz, MD, PhD c, Raquel Rivera, MD d, Esteban Daudén, MD, PhD e, Fran J. Gómez-García, MD f, Pablo de la Cueva, MD, PhD g, Enrique Herrera-Ceballos, MD, PhD h, Isabel Belinchón, MD, PhD i, José Luis López-Estebaranz, MD j, Mercè Alsina, MD, PhD k, José Luis Sánchez-Carazo, MD, PhD l, Marta Ferrán, MD m, Ofelia Baniandrés, MD, PhD n, José Manuel Carrascosa, MD, PhD c, Mar Llamas-Velasco, MD, PhD e, Diana Ruiz-Genao, MD j, Enrique Herrera-Acosta, MD h, Carlos Muñoz-Santos, MD, PhD o, Ignacio García-Doval, MD, PhD a, p
the
, Gregorio Carretero, MD, PhD b, Carlos Ferrándiz, MD, PhD c, Raquel Rivera, MD d, Esteban Daudén, MD, PhD e, Fran J. Gómez-García, MD f, Pablo de la Cueva, MD, PhD g, Enrique Herrera-Ceballos, MD, PhD h, Isabel Belinchón, MD, PhD i, José Luis López-Estebaranz, MD j, Mercè Alsina, MD, PhD k, José Luis Sánchez-Carazo, MD, PhD l, Marta Ferrán, MD m, Ofelia Baniandrés, MD, PhD n, José Manuel Carrascosa, MD, PhD c, Mar Llamas-Velasco, MD, PhD e, Diana Ruiz-Genao, MD j, Enrique Herrera-Acosta, MD h, Carlos Muñoz-Santos, MD, PhD o, Ignacio García-Doval, MD, PhD a, pthe
Biobadaderm Study Group
a Research Unit, Fundación Piel Sana AEDV, Madrid, Spain
b Department of Dermatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain
c Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain
d Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
e Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain
f Department of Dermatology, Hospital Universitario Reina Sofía, Cordoba, Spain
g Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
h Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
i Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
j Department of Dermatology, Fundación Hospital de Alcorcón, Madrid, Spain
k Department of Dermatology, Hospital Clinic, Barcelona, Spain
l Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
m Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
n Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
o Department of Dermatology, Hospital General Granollers, Barcelona, Spain
p Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
∗Correspondence to: Miguel Angel Descalzo, MSc, PhD, Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Ferraz 100, 1° izda, Madrid 28008, SpainResearch UnitFundación Piel Sana Academia Española de Dermatología y VenereologíaFerraz 100, 1° izdaMadrid28008Spain
| Funding sources: The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, and Janssen). |
|
| Disclosure: Dr Carretero has been reimbursed by Janssen, Abbvie, Novartis, Pfizer, MSD, and Celgene for advisory service and conference participation. Dr Ferrándiz has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Lilly, Merck Sharp & Dohme, Novartis, and Pfizer. Dr Rivera has participated in a speaker’s bureau for Abbott, Janssen, MSD, and Pfizer-Wyeth. Dr Dauden has acted as consultant for Abbott, Amgen, Astellas, Centocor Ortho Biotech Inc, Galderma, Glaxo, Jansenn-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; received honoraria form Abbott, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; participated in a speakers bureau for Abbott, Pfizer, MSD, and Janssen; and received grants from Pfizer, Abbott, Janssen, and MSD. Dr De la Cueva has acted as a consultant and speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, and Leo-Pharma. Dr Herrera-Ceballos has served as a consultant and/or speaker for and/or participated in clinical trials as principal investigator and sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. Dr Belinchón acted as a consultant for Pfizer-Wyeth, Janssen Pharmaceuticals, MSD, Almirall SA, Lilly, and Leo-Pharma and as an invited speaker for AbbVie, Pfizer-Wyeth, Janssen Pharmaceuticals, Novartis, and MSD. Dr López-Estebaranz has participated in advisory boards and received educational grants from Janssen, Abbvie, MSD, Lilly, Novartis, LeoPharma, and Pfizer. Dr Alsina has given expert testimony for Merck-Schering Plough and Abbott. Dr Carrascosa has participated as a speaker and/or advisor for Celgene, Janssen, Lilly, Novartis, Leo Pharma, Pfizer, MSD, Abbvie, Biogen, and Amgen. Dr Ferran has acted as a consultant for Abbott, Janssen, MSD, and Pfizer-Wyeth; participated in a speaker's bureau for MSD and Janssen; and received grants from Serono. Dr Baniandrés has acted as a consultant for Abbvie, Janssen, Pfizer-Wyeth, and Novartis. Dr Herrera-Acosta has served as a consultant and/or speaker with Leo Pharma, Novartis, Janssen, Lilly, Celgene, and Abbvie. Dr Muñoz-Santos has acted as a consultant for Abbott, Janssen, and Pfizer; received honoraria from Abbott, Janssen, Merck Pfizer-Wyeth; and Schering-Plough; given expert testimony for Abbott, Janssen, Wyeth, and Schering-Plough; and received grants from Janssen and Wyeth. Dr Garcia-Doval has received travel grants for congresses from MSD, Pfizer, and Schering. Drs Descalzo, Gómez-García, Sánchez-Carazo, Llamas-Velasco, Ruiz-Genao, and García-Doval have no conflicts of interest to disclosed. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 4
P. 798-800 - avril 2018 Retour au numéro
Article précédent
- Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades III-V skin: A prospective randomized clinical trial
- Jeong-Wan Seo, Ki-Hoon Song
- Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study
- Arvin Ighani, Jorge R. Georgakopoulos, Neil H. Shear, Scott Walsh, Jensen Yeung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?